|
tyyppi |
julkaisu |
| 3 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 11 |
Lehti |
Bailey LC, Orosz ST.
Stability of ceftriaxone sodium and metronidazole hydrochloride.
Am J Health-Syst Pharm 1997 ; 54: 424-427. |
| 59 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 62 |
Lehti |
Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125. |
| 84 |
Lehti |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 91 |
Lehti |
Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210. |
| 95 |
Lehti |
Pritts D, Hancock D.
Incompatibility of ceftriaxone with vancomycin.
Am J Hosp Pharm 1991 ; 48: 77. |
| 99 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 100 |
Lehti |
Plumridge RJ, Rieck AM, Annus TP, Langton SR.
Stability of ceftriaxone sodium in polypropylene syringes at -20, 4, and 20°C.
Am J Health-Syst Pharm 1996 ; 43: 2320-2323. |
| 150 |
Lehti |
Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35. |
| 169 |
Lehti |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 198 |
Lehti |
Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 215 |
Lehti |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 241 |
Lehti |
Leader WG, Jones JM.
Incompatibility between ceftriaxone sodium and labetolol hydrochloride.
Am J Health-Syst Pharm 1996 ; 53: 2639. |
| 244 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 |
Lehti |
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 |
Lehti |
Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 259 |
Lehti |
Bailey LC, Tang KT, Medwick T.
Stability of ceftriaxone sodium in infusion-pump syringes.
Am J Hosp Pharm 1993 ; 50: 2092-2094. |
| 275 |
Lehti |
Lewis JD, El-Gendy A.
Cephalosporin-pentamidine isethionate incompatibilities.
Am J Health-Syst Pharm 1996 ; 53: 1461-1462. |
| 276 |
Lehti |
Parrish MA, Bailey LC, Medwick T.
Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures.
Am J Hosp Pharm 1994 ; 51: 92-94. |
| 279 |
Lehti |
Bailey LC, Cappel KM, Orosz ST.
Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes.
Am J Hosp Pharm 1994 ; 51: 2159-2161. |
| 282 |
Lehti |
Rivers TE, Webster AA.
Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags.
Am J Health-Syst Pharm 1995 ; 52: 2568-2570. |
| 299 |
Lehti |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Lehti |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 315 |
Lehti |
Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600. |
| 317 |
Lehti |
Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362. |
| 335 |
Lehti |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 336 |
Lehti |
Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409. |
| 337 |
Lehti |
Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533. |
| 432 |
Lehti |
Marble DA, Bosso JA, Townsend RJ.
Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions.
Am J Hosp Pharm 1986 ; 43: 1732-1736. |
| 479 |
Lehti |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 492 |
Lehti |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 |
Lehti |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 587 |
Lehti |
Smith BR.
Effect of storage temperature and time stability of cefmenoxime, ceftriaxone, and cefotetan in 5% dextrose injection.
Am J Hosp Pharm 1983 ; 40: 1024-1025. |
| 589 |
Lehti |
Kedzierewicz F, Finance C, Nicolas A, Dixneuf P, Hoffman M.
Stability of parenteral ceftriaxone disodium solutions in frozen and liquid states: effect of freezing and microwave thawing.
J Pharm Sci 1989 ; 78: 73-77. |
| 604 |
Laboratorio |
Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998 |
| 640 |
Lehti |
Walker SE, Dranitsaris G.
Stability of reconstituted ceftriaxone in dextrose and saline solutions.
Can J Hosp Pharm 1987 ; 40: 161-166. |
| 649 |
Lehti |
Das Gupta V.
Stability of ceftriaxone sodium when mixed with metronidazole injection.
Int J Pharm Compound 1997 ; 1: 280-281. |
| 905 |
Lehti |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 939 |
Lehti |
Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 1135 |
Lehti |
Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077. |
| 1410 |
Lehti |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Lehti |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Lehti |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1452 |
Lehti |
Muller HJ, Howe K, Frank C, Haker I.
Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*.
Eur Hosp Pharm 2000 ; 6: 17-23. |
| 1508 |
Lehti |
Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124. |
| 1611 |
Lehti |
Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506. |
| 1625 |
Lehti |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1638 |
Lehti |
O'Connell C, Sabra K, Scott K.
Stability of reconstituted ceftriaxone solution in polypropylene syringes.
Eur Hosp Pharm 1996 ; 2: 47-48. |
| 1659 |
Lehti |
Xu QA, Trissel LA, Williams KY.
Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics.
J Am Pharm Assoc 2000 ; 40: 509-514. |
| 1674 |
Lehti |
Trissel LA, Gilbert DL, Martinez JF.
Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 1515-1522. |
| 1712 |
Lehti |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Lehti |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Lehti |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1744 |
Lehti |
Burkiewicz JS.
Incompatibility of ceftriaxone sodium with lactated Ringer’s injection.
Am J Health-Syst Pharm 1999 ; 56: 384. |
| 1754 |
Lehti |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1800 |
Lehti |
Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855. |
| 1803 |
Lehti |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1840 |
Lehti |
Xu QA, Trissel LA, Saenz CA et al.
Stability of three cephalosporin antibiotics in autodose infusion system bags.
J Am Pharm Assoc 2002 ; 42: 428-431. |
| 1847 |
Lehti |
Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G.
Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration.
J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241. |
| 1902 |
Lehti |
Walker SE, Wyllie A, Law S.
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.
Can J Hosp Pharm 2004 ; 57, 2: 90-96. |
| 1925 |
Lehti |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1937 |
Lehti |
Lai JJ, Brodeur SK.
Physical and chemical stability of daptomycin with nine medications.
Ann Pharmacotherapy 2004 ; 38: 1612-1616. |
| 1953 |
Lehti |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1982 |
Lehti |
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2110 |
Lehti |
Hecq JD, Evrard JM, Vanbeckbergen DF, Jamart J, Galanti LM.
Effect of freezing, long term storage and microwave thawing on the stability of ceftriaxone sodium in 5% dextrose infusion polyolefin bags at 2-8°C.
EJHP Science 2006 ; 12, 3: 52-56. |
| 2233 |
Lehti |
Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457. |
| 2238 |
Laboratorio |
Clinomel - Résumé des caractéristiques du produit
Baxter 2018 |
| 2247 |
Lehti |
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278. |
| 2271 |
Laboratorio |
Daptomycine (Cubicin®) Résumé des caractéristiques du produits
Novartis 2006 |
| 2302 |
Laboratorio |
Ceftriaxone et incompatibilités physico-chimiques, particulièrement avec les solutions contenant des sels de calcium.
Lettre AFFSAPS 30 November 2008 2008 ; 61, 5: 356-357. |
| 3012 |
Lehti |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3216 |
Lehti |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3254 |
Lehti |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3408 |
Lehti |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3520 |
Laboratorio |
Cidomycin - Summary of product Chracteristics.
Sanofi 2011 |
| 3523 |
Laboratorio |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018 |
| 3526 |
Laboratorio |
Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010 |
| 3549 |
Laboratorio |
Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012 |
| 3560 |
Laboratorio |
Linezolid (Zyvox®) - Summary of Product Characteristics
Pharmacia 2013 |
| 3571 |
Lehti |
Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47. |
| 3643 |
Laboratorio |
Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015 |
| 3644 |
Laboratorio |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3674 |
Laboratorio |
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016 |
| 3728 |
Lehti |
Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291. |
| 3766 |
Lehti |
Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 |
Lehti |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3791 |
ilmoitus |
Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014 |
| 3824 |
Lehti |
Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98 |
| 3827 |
ilmoitus |
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015 |
| 3828 |
ilmoitus |
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015 |
| 3829 |
ilmoitus |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015 |
| 3964 |
Lehti |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 3976 |
Lehti |
Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218 |
| 4055 |
Lehti |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4144 |
Lehti |
Ross A, Boddu S, Mauro V, Churchwell M.
Physical compatibility of milrinone with levofloxacin and ceftriaxone injection.
EJHP 2018 ;75,14:1010-1012 |
| 4145 |
Lehti |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
| 4319 |
Lehti |
Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4440 |
Lehti |
Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Ann Nutr Metab 2018 ; 73: 227-233. |
| 4603 |
Lehti |
Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4654 |
ilmoitus |
Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021 |
| 4693 |
Lehti |
Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L.
Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection.
Drug Design Dev Ther 2022 ;16:1433-1440. |
| 4742 |
Lehti |
Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 |
Lehti |
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1: |
